Celgene successfully blocks Apotex's bid for inter partes review of REVLIMID® patent
Client(s) Celgene Corporation
Jones Day represented Celgene Corporation in successfully blocking institution of an inter partes review (IPR) petition filed by Apotex against U.S. Patent No. 8,741,929, which is listed in the Orange Book for Celgene's REVLIMID® brand drug. The '929 patent is directed to the use of REVLIMID® for the treatment of mantle cell lymphoma. Following Celgene's filing of its Patent Owner Preliminary Response, the Patent Trial and Appeal Board (PTAB) denied Apotex's petition in its entirety and declined to institute an IPR, finding that Apotex had failed to establish a reasonable likelihood that it would prevail in showing the unpatentability of any challenged claim of the '929 patent.
Apotex Inc., et al. v. Celgene Corp., IPR No. 2018-00685 (PTAB)